New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Tom Nolan reviews this week’s research There’s certainly a gap in the market for an effective third or fourth line antihypertensive. A trial of lorundrostat, an aldosterone synthase inhibitor, found a ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

For extra enjoyment, she dips her tenders in her mashed potatoes. She says that she lost 200 lbs. "naturally though calorie ...